SCHEMBL5906800

SCHEMBL5906800

COC(=O)[C@H](Cc1ccccc1)Nc1cc(-c2ccc(CNc3ccccc3)cc2)ncn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 9/20 0.52
HSD17B10 Q99714 8/20 0.52
CLK4 Q9HAZ1 7/20 0.52
ALDH1A1 P00352 7/20 0.52
CYP2D6 P10635 5/20 0.52
CYP3A4 P08684 5/20 0.49
CYP2C19 P33261 5/20 0.49
TP53 P04637 4/20 0.49
MAPK1 P28482 4/20 0.49
TSHR P16473 3/20 0.49
HIF1A Q16665 2/20 0.49
MAPT P10636 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46
ATM Q13315 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5906797 1.00 CYP1A2 (0.52) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906948 0.90 CYP1A2 (0.53) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906943 0.90 CYP1A2 (0.53) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906697 0.89 TACR3 (0.47) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906837 0.89 TACR3 (0.47) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906841 0.89 TACR3 (0.47) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906701 0.89 TACR3 (0.47) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906667 0.88 TACR3 (0.46) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906665 0.88 TACR3 (0.46) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6
SCHEMBL5906861 0.87 ELANE (0.48) CYP1A2HSD17B10CLK4ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089371-A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist BAYER HEALTHCARE AG (DE) 2006-04-27 US disclosed
EP-1575919-A1 PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST Bayer HealthCare AG (DE) 2005-09-21 EP disclosed
WO-2004043926-A1 PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST BAYER HEALTHCARE AG (DE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089371-A1 Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist BPHL, HRH4, HRH2 CYP1A2 625/4885HSD17B10 1916/4885CLK4 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.